US · IMNM · BIOTECHNOLOGY
Immunome, Inc. (IMNM) intrinsic value and stock valuation
$15.69as of 2026-11-21 · Mkt cap 2.39B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Immunome, Inc. DCF and intrinsic value
InvestorsCraft values IMNM with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from IMNM’s statements →
Immunome, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.94M | $9.04M | $14M | $0.00 | $0.00 |
| Operating income | -$-214.11M | -$-305.8M | -$-109.53M | -$-36.9M | -$-25.2M |
| Net income | -$-212.39M | -$-292.96M | -$-106.81M | -$-36.9M | -$-24.71M |
| EPSd | -$-2.43M | -$-5M | -$-5.38M | -$-3.04M | -$-2.14M |
| Operating cash flow | -$-190.92M | -$-110.79M | -$-7.57M | -$-28.69M | -$-18.23M |
| Capital expenditure | -$-9.69M | -$-53.51M | -$-830K | -$-250K | -$-80K |
| Free cash flow | -$-200.6M | -$-164.3M | -$-8.4M | -$-28.94M | -$-18.3M |
| Total assets | $683.2M | $240.2M | $148.5M | $24.1M | $57.9M |
| Total debt | $3.85M | $4.83M | $1.65M | $290K | $320K |
| Net debt | -$-649.63M | -$-138.52M | -$-97.03M | -$-20.03M | -$-48.91M |
| Total equity | $634.3M | $181.2M | $119.9M | $16.7M | $48.2M |
| Cash and short-term investments | $653.5M | $217.3M | $138.1M | $20.3M | $49.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.94M | $9.04M | $14M | $0.00 | $0.00 |
| Cost of revenue | $2.96M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $3.99M | $9.04M | $14M | $0.00 | $0.00 |
| Research and development expenses | $174.3M | $129.5M | $23.1M | $23.3M | $14.1M |
| Selling, general and administrative expenses | $43.8M | $33M | $19.7M | $13.6M | $11.1M |
| Other expenses | $0.00 | $152.3M | $80.8M | $0.00 | $0.00 |
| Operating expenses | $218.1M | $314.8M | $123.6M | $36.9M | $25.2M |
| Cost and expenses | $221.1M | $314.8M | $123.6M | $36.9M | $25.2M |
| Interest income | $11.7M | $12.8M | $2.72M | $10K | $10K |
| Interest expense | $0.00 | $0.00 | $0.00 | $10K | $10K |
| Depreciation and amortization | $2.96M | $2.1M | $730K | $630K | $760K |
| Ebitda | -$-209.44M | -$-151.35M | -$-28M | -$-36.26M | -$-23.95M |
| Operating income | -$-214.11M | -$-305.8M | -$-109.53M | -$-36.9M | -$-25.2M |
| Total other income/expenses, net | $1.72M | $12.8M | $2.72M | $10K | $490K |
| Income before tax | -$-212.39M | -$-292.96M | -$-106.81M | -$-36.9M | -$-24.71M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-212.39M | -$-292.96M | -$-106.81M | -$-36.9M | -$-24.71M |
| Weighted average shares outstanding | $87.4M | $58.6M | $19.8M | $12.1M | $11.5M |
| Weighted average diluted shares outstanding | $87.4M | $58.6M | $19.8M | $12.1M | $11.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $653.5M | $217.3M | $138.1M | $20.3M | $49.2M |
| Net receivables | $0.00 | $0.00 | $290K | $850K | $4.31M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $660.8M | $221.3M | $144.7M | $22.7M | $56.6M |
| Property, plant and equipment, net | $17.6M | $14.4M | $3.64M | $960K | $850K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $210K | $0.00 | $100K | $0.00 | $100K |
| Total non-current assets | $22.4M | $18.9M | $3.84M | $1.4M | $1.29M |
| Total assets | $683.2M | $240.2M | $148.5M | $24.1M | $57.9M |
| Accounts payable | $3.34M | $14.2M | $3.31M | $2.4M | $3.08M |
| Short-term debt | $0.00 | $60K | $310K | $230K | $320K |
| Deferred revenue | $0.00 | $6.94M | $10.5M | $0.00 | $0.00 |
| Total current liabilities | $45M | $54.3M | $21.8M | $7.33M | $9.73M |
| Long-term debt | $3.85M | $4.77M | $1.34M | $60K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $5.49M | $0.00 | $0.00 |
| Total non-current liabilities | $3.85M | $4.77M | $6.83M | $60K | $10K |
| Capital lease obligations | $0.00 | $4.83M | $1.65M | $290K | $320K |
| Total liabilities | $48.8M | $59.1M | $28.7M | $7.39M | $9.74M |
| Common stock | $10K | $10K | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-728.16M | -$-515.77M | -$-222.81M | -$-116M | -$-79.11M |
| Accumulated other comprehensive income (loss) | $0.00 | $60K | $20K | $0.00 | -$-57.92M |
| Total equity | $634.3M | $181.2M | $119.9M | $16.7M | $48.2M |
| Total investments | $210K | $74M | $39.6M | $0.00 | $100K |
| Total debt | $3.85M | $4.83M | $1.65M | $290K | $320K |
| Net debt | -$-649.63M | -$-138.52M | -$-97.03M | -$-20.03M | -$-48.91M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-212.39M | -$-292.96M | -$-106.81M | -$-36.9M | -$-24.71M |
| Depreciation and amortization | $2.96M | $2.1M | $730K | $630K | $760K |
| Stock-based compensation | $25.7M | $15.8M | $6.22M | $5.33M | $3.45M |
| Change in working capital | -$-15.23M | $14.9M | $12M | $2.24M | $2.78M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-9.16M | $9.53M | -$-610K | -$-680K | $1.78M |
| Net cash provided by operating activities | -$-190.92M | -$-110.79M | -$-7.57M | -$-28.69M | -$-18.23M |
| Investments in property, plant and equipment | -$-9.69M | -$-7.17M | -$-830K | -$-250K | -$-80K |
| Acquisitions, net | $0.00 | $0.00 | $9.28M | $0.00 | $0.00 |
| Net cash used for investing activities | $60.8M | -$-85.06M | -$-30.48M | -$-250K | -$-80K |
| Common stock issued | $640.4M | $250M | $30K | $30K | $27.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $640.4M | $240.5M | $116.4M | $30K | $27.8M |
| Net change in cash | $510.2M | $44.7M | $78.4M | -$-28.91M | $9.46M |
| Cash at end of period | $653.7M | $143.5M | $98.8M | $20.4M | $49.3M |
| Operating cash flow | -$-190.92M | -$-110.79M | -$-7.57M | -$-28.69M | -$-18.23M |
| Capital expenditure | -$-9.69M | -$-53.51M | -$-830K | -$-250K | -$-80K |
| Free cash flow | -$-200.6M | -$-164.3M | -$-8.4M | -$-28.94M | -$-18.3M |
Line items
Line items
Line items
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- CEO
- Clay Siegall
- Employees
- 177
- Beta
- 2.07
Explore
Frequently asked questions
What is the intrinsic value of Immunome, Inc. (IMNM)?
Immunome, Inc. (IMNM) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IMNM undervalued?
IMNM trades at a price of $15.69 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.